Introduction {#s1}
============

During development, radial glial cells are the primary neural stem cells developing all neurons such as astrocytes, microglia cells, ependymal cells, and oligodendrocytes ([@B113]). Mature astrocytes are categorized for functional and morphology proprieties. In the frontal cortex, these cells can be morphologically distinguished in four types: fibrous astroglia, protoplasmic, varicose, and interlaminar projections placed in the white matter and I, II, III, IV, V, and VI layers ([@B118]). Other functional and morphological distinct astrocytes are unipolar Bergmann glia with radial ascending processes and elongated radial glia-like tanycytes. In the cerebellum, Bergmann glia control the synapsis of Purkinje cells ([@B27]), while in the hypothalamus, tanycytes are specialized in the modulation of neuroendocrine functions ([@B86]). One of the most important astrocytes function is to deliver energy to neurons by the astrocyte-neuron lactate shuttle ([@B4]; [@B99]). Astrocytes modulate Ca^2+^ variations that influence neuronal activity releasing gliotransmitters ([@B85]). The modulation of the neurotransmitter uptake involves the excitatory transporters 1 and 2 (EAAT1 and 2) ([@B90]). In response to inflammation and injury, astrocytes become reactive. They can be divided in two main categories: scar-forming astrocytes and hypertrophic astrocytes ([@B54]). Several studies underline that reactive astrocytes alter them homeostatic functions such as potassium ion uptake, ion buffering, Ca^2+^ signaling, and excitatory neurotransmitter uptake ([@B91]). Regulation of astrocytes functions affected several brain pathologies such as Alzheimer disease, Huntington disease, Ischemic stroke, and epilepsy.

Alzheimer Disease {#s2}
=================

AD is a neurodegenerative disease with motor abnormalities, cognitive changes, and behavioral impairment. It is characterized by the aggregation of amyloid-β plaques in vessel walls and accumulation of the protein tau in neural cells. Astrocytes in this pathology contribute to the loss of neuroprotection and to the gaining of pathological characteristics. At the beginning, astrocytes have a protective role up-taking and degrading amyloid-β. The progression of disease leads to reduced astrocyte clearance of amyloid-β that contribute to gain of function ([@B36]). Furthermore, amyloid-β accumulation stimulates astrocytes to produce pro-inflammatory mediators inducing a positive feedback of activation ([@B41]).

It has been shown that amyloid-β co-operates with several receptors located on astrocytes such as scavenger receptors, TLRs, lipoprotein, glycoprotein and acetylcholine receptors, chemokine, and complement receptors ([@B30]). Scavenger receptors are a group of evolutionally conserved membrane receptors expressed on the surface of microglia, macrophages, and dendritic cells ([@B127]). To date, they have been classified into six classes (scavenger receptor A, B, C, D, E, and F) even if some members of this family remain unclassified (RAGE, CD163, and SR-PSOX). Of particular interest during AD are CD36, RAGE (receptor for advanced glycation end products), SCARA-1 (scavenger receptor A-1), and MARCO (macrophage scavenger receptor with collagenous structure). SCARA-1 is involved in clearance of Aβ, while MARCO forms a complex with formyl peptide--receptor-like 1 (FPR1) upon encountering Aβ. MARCO may decrease the inflammatory response in microglia through the FPR-1 *via* the ERK 1/2 intracellular signaling and the inhibition of cAMP ([@B9]). CD36 and RAGE are implicated in activation of microglia by Aβ. CD36 cooperates with the other innate immune pattern recognition receptor like the TLRs to outline pathogen-specific responses. Once engaged by Aβ, CD36 forms a complex with TLR-6 and TLR-4 causing ROS production and inflammasome activation ([@B107]). RAGE receptor is one of the most characterized unclassified scavenger receptor and has been reported to produce proinflammatory modifications in astrocytes when binds amyloid-β ([@B41]). RAGE in turn activates the NF-κB ([@B131]) and its downstream pathway including p21, Cdc42-Rac, ras, MAPK ([@B110]), ERK ([@B127]), and JNK ([@B41]). RAGE is highly expressed vasculature and neurons in AD brains compared with the un-diseased ([@B3]). RAGE located on endothelial cells in implicated in transporting Aβ into the brain ([@B71]), and also increasing the diapedesis of monocytes across the blood--brain barrier ([@B38]). Once bound to soluble Aβ, RAGE induces microglial activation and chemotaxis following a concentration gradient, leading to a microglial accumulation around Aβ plaques ([@B127]). RAGE mediates also the phagocytic profile of astrocytes and the interaction with other ligands, including S100β, involved in Alzheimer disease neuroinflammation ([@B19]). S100β produced by astrocytes is a common feature of Alzheimer disease ([@B7]). It is associated with depressive behavior and cognitive flexibility and regulates neuronal oscillations ([@B109]; [@B11]).

Moreover, morphological modifications of astrocytes in Alzheimer disease involve alterations in K^+^ neurovascular regulation, by downregulation of Kir4.1 and BK~Ca~, causing irregular cerebral blood flow ([@B41]). Also, Ca^2+^ signaling is altered by amyloid-β accumulation ([@B42]). In astrocytes, this accumulation modifies the expression of the nicotinic acetylcholine receptors (nAchRs) and metabotropic glutamate receptor 5 (mGluR5), changing Ca^2+^ homeostasis ([@B130]; [@B68]). Through this pathway, astrocytes increase glutamate signaling and led to the downregulation of its transporters ([@B73]). Glutamate aberrant trafficking is linked to the modified cholesterol synthesis ([@B114]; [@B76]; [@B111]). A prodromal symptom to Alzheimer's disease can be the glucose hypometabolism ([@B78]). Carriers of apolipoprotein Eε4 (APOEε4) allele display lower glucose metabolism in different brain area with an augmented risk for AD ([@B89]). Astrocytes signaling is a useful target to prevent and control the development of the AD.

Huntington Disease {#s3}
==================

Huntington disease is a genetic neurodegenerative disease with neuropsychiatric and motor dysfunctions. It is caused by a trinucleotide repeat (CAG) in the gene for Htt. This expansion caused a different form of Htt (mHtt) which aggregates ([@B13]). Astrocytes are more efficient than neurons in clearance of aggregates, so they are more resistant to mHtt accumulation ([@B137]; [@B47]; [@B138]). However, when mHtt aggregates into astrocytes modifies glutamate signaling, causing neuronal excitotoxicity ([@B101]; [@B8]). This condition is a typical feature of Huntington disease but has also been described several cases without alteration in glutamate release ([@B83]). Astrocytes in Huntington disease are characterized by a decreased expression of Kir4.1 ([@B115]; [@B135]). It influences GLT1-mediated homeostasis and Ca^2+^ signaling ([@B115]; [@B51]). These dysfunctions head the reactive state of astrocytes bringing about the possibility neurotoxicity can induce inflammation as secondary effect of Huntington disease ([@B115]).

During the inflammatory state, microglia trigger the activation of astrocytes releasing factors such as TNF-α, C1q, and IL-1α ([@B56]; [@B67]). They decreased synaptic maintenance and phagocytic activity ([@B8]) and increase degeneration neurons and oligodendrocytes ([@B67]).

mHtt accumulation modifies astrocytes exosome ([@B44]) and BDNF ([@B43]) release. Restoration of BDNF expression from astrocytes displays neuroprotective effects ([@B37]; [@B43]; [@B88]). It has been displayed that astrocytes are intricated in a wide range of pathological features of Huntington disease, so they can be used as a novel therapeutic target.

Epilepsy {#s4}
========

Epilepsy is a group of brain disorders characterized by unpredictable and periodic occurrence of seizures. The cause of most cases of epilepsy is unknown. Some cases occur as the result of brain injury, stroke, brain tumors, infections of the brain, and birth defects through a process known as epileptogenesis ([@B39]). Known genetic mutations are directly linked to a small proportion of cases ([@B82]). Although the symptoms of a seizure may affect any part of the body, the electrical events that produce the symptoms occur in the brain. Epileptic seizures are the result of excessive and abnormal neuronal activity in the cortex of the brain ([@B32]).

The most common of these pathologies is the hippocampal sclerosis or mesial temporal sclerosis. It is characterized by gliosis, neuronal cell loss in the hippocampal areas, synaptic reorganization, and microvascular proliferation. A study published in PloS Biology shows how the interaction between neurons and astrocytes is one of the mechanisms that contributes to the generation of epileptic discharges. Believed in the past to be simple "helpers" of neurons, astrocytes have revealed over time cells that play a much more active role in the brain ([@B40]). Astrocytes express ion channels, transmitter receptors, and transporters and, thus, are endowed with the machinery to sense and respond to neuronal activity. Glutamate transporters are located on several neuronal cell types, but astrocytes are mainly involved in the glutamate uptake ([@B105]). GLT-1, the glutamate transporter located on astrocytes, is involved in the bulk of extracellular glutamate clearance and is responsible of the increased levels in epileptogenic foci. Moreover, glutamine synthetase is reduced in the hippocampus of temporal lobe epilepsy patients compared to the healthy one. This downregulation leads to a slow glutamate--glutamine cycling and an accumulation of the transmitter in the extracellular space and astrocytes, providing a metabolic mechanism for astrocyte-dependent hyperexcitability. A few studies have highlighted the contribution of ionotropic glutamate receptors in convulsion generation. AMPA receptors, in particular the subtype composed by subunits GluR1 to GluR4, are abundantly expressed on astrocytes. Epilepsy patients show an enhanced expression of GluR1 flip variants accounts for the prolonged receptor in hippocampal astrocytes. Prolonged receptor opening increases influx of Na^+^ and Ca^2+^ ions, blocking astroglial Kir channels which increase depolarization reducing the K^+^ buffering capacity of astrocytes ([@B106]). All this process contributes to hyperexcitability. In this condition, extracellular \[K^+^\] could increase from ∼ 3 mM to 10--12 mM; and glial cells take the most K^+^ released by active neurons. As already mentioned, the primary mechanism for spatial K^+^ buffering and K^+^ reuptake is *via* glial inwardly rectifying K^+^ channels (Kir channels). Kir channel subtypes (Kir1--Kir7) differ in functional properties and tissue distribution; Kir4.1 is the most abundantly in brain astrocytes. Astrocytes are also joined by gap junctions, which allow these cells to redistribute through the glial network the K^+^ ions excessively accumulated at sites of intense neuronal activity. Accordingly, increasing evidence indicates that dysfunctional astrocytes are crucially involved in processes leading to epilepsy ([@B104]).

Ischemic Stroke {#s5}
===============

Ischemic stroke is a brain damage which can lead to death or disabilities. It results from a vasculature dysfunction with occlusion of blood vessels by embolus or thrombus. The reduced or blocked blood flow causes loss of oxygen and glucose and in turn synthesis of ATP *via* glycolysis and oxidative phosphorylation. These conditions produce excitotoxicity and malfunction of astrocytes glutamate transporters, fundamental in the synaptic cleft in clearing glutamate release ([@B132]; [@B140]). Increased glutamate release in the extracellular area induces the overexpression of rNMDARs and caused overloading of intracellular Ca^2+^ ([@B112]; [@B74]). This energy depletion influences membrane potential depolarization and ionic gradients in neurons and astrocytes. In particular, astrocytes, comparing neurons, are less susceptible to glutamate cytotoxicity induced by brain stroke, but they display proliferation and up-regulation of GFAP levels producing reactive astrogliosis ([@B102]). Reactive astrocytes are usually found in the focal lesions with tissues reorganization and formation of glial scars ([@B102]). White matter astrocytes are especially sensible to ischemic stroke ([@B16]). The ischemic core shows a predominant presence of hypertrophic astrocytes with a larger Ca^2+^ signal compared to the penumbra region, the area surrounding the ischemic locus ([@B28]). Transcriptome analysis of activated astrocytes from inflamed brain after middle cerebral artery occlusion shows expression of genes encoding neuroprotective mediators and included cytokines (IL-6, IL-1, IL-1β, IL-10), transforming growth factor-β (TGFβ), interferon-γ (IFN-γ), thrombospondins, and neurotrophic factors ([@B134]). High levels of cytokines induce increasing levels of nitric oxide (NO) ([@B108]) and apoptosis of neuronal cells ([@B20]) and inhibit neurogenesis ([@B77]). Reactive astrocytes also release chemokines after ischemia ([@B58]). In vascular endothelial cells, chemokines increased adhesion molecules levels, attracting immune cells ([@B102]). Astrocytes are the first cells of the nervous system where the class II major histocompatibility complex (MHC) ([@B29]) was shown. MHC II presents antigens to CD41 T-helper cells and is expressed on antigen presenting cells (APCs). Moreover, astrocytes express pattern recognition receptors (PRRs) as scavenger receptor, TLRs, and complement proteins playing a role in immune response regulation ([@B12]).

These features let us to consider astrocyte a possible regulator of the ischemic context, considering that chronic of inflammation is influenced by the degree of tissue injury and exacerbation of the damage.

Discussion {#s6}
==========

To date, only five drugs are accepted by the Food and Drug Administration (FDA) for the cure of AD: donepezil, galantamine and rivastigmine, memantine, and a drug composed of donezil and memantine ([**Table 1**](#T1){ref-type="table"}). Unfortunately, the use of these drugs is aimed at improving the excellence of life of patients, and they are not capable to stop the progression of the disorder ([@B15]). So, it is important to find innovative treatments that improve therapeutic results. Aβ plaques increase the proinflammatory cytokines ([@B84]; [@B21]) and the production of free radicals ([@B14]; [@B128]) with consequent activation of the astrocytes. In a late study conducted on APP/PS1 transgenic mice and on mixed neuronal/glial cultures, it was shown that curcumin improves spatial memory, stimulates cholinergic neuronal function, and, through PPAR-γ, reduces the activation of the inflammatory process in microglia and astrocytes ([@B41]). Additional natural phytochemicals have demonstrated an anti-inflammatory and immunosuppressive capacities in AD models ([**Table 1**](#T1){ref-type="table"}), e.g., the triptolide extract inhibits astrocyte activation in the APP/PS1 transgenic mouse model of AD ([@B64]). Punicalagin, a pomegranate derivative, reduces neuroinflammation (lowering TNF-α and IL-β) and also prevents oxidative stress by reducing iNOS, COX-2, and ROS production ([@B59]). Other mixtures that may have a probable role against dementia ([@B66]) are cannabinoid agonists such as WIN, 2-AG, and methanandamide ([**Table 1**](#T1){ref-type="table"}) that have shown anti-inflammatory activities in primary astrocytes grown later exposure to Aβ~1--42~ or Aβ~25--35~ ([@B1]; [@B35]). Other approaches to diminish oxidative stress in AD models involve stimulants of endogenous antioxidant factors ([**Table 1**](#T1){ref-type="table"}) such as pelargonidine ([@B103]), Bambusae concretio Silicea ([@B49]), and the new compound Monascin ([@B100]). In *in vivo* and in *in vitro* analyses, it has been shown that exogenous antioxidant compounds ([**Table 1**](#T1){ref-type="table"}) also have beneficial effects. Among these, we have resveratrol ([@B121]), tocotrienol (vitamin E) ([@B46]), anthocyanins ([@B87]), epicatechin ([@B25]), and 3H-1,2-dithiole-3-thione (a powerful free radical scavenger) ([@B123]). Aβ accumulation from astrocytes can also be decreased using IL-1β or TNF-α/TNF-α, PPAR-γ receptor agonists, minocycline or nicergoline, and tyrosine kinase inhibitors ([@B120]; [@B60]; [@B72]; [@B116]). NSAIDs are drugs that bind to and activate the PPAR-γ receptor ([@B48]; [@B126]) leading to reduced activation of glial cells ([@B23]; [@B5]) and cytokine-mediated inflammation ([@B95]; [@B26]).

###### 

Neurologically active drugs.

  Disease                                                                                                                                                        Drug category                                                                                                                      References
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  AD                                                                                                                                                             FDA accepted                                                                                                                       Donepezil, galantamine, rivastigmine, memantine, and donezil + memantine ([@B15])
  Natural phytochemicals                                                                                                                                         Triptolide extract ([@B64]) and punicalagin ([@B59])                                                                               
  Cannabinoid agonists                                                                                                                                           WIN, 2-AG, and methanandamide ([@B1]; [@B35])                                                                                      
  Endogenous antioxidant factors                                                                                                                                 Pelargonidine ([@B103]), Bambusae concretio Salicea ([@B49]), monascin ([@B100])                                                   
  Exogenous antioxidant compounds                                                                                                                                Resveratrol ([@B121]), tocotrienol ([@B46]), anthocyanins ([@B87]), epicatechin ([@B25]), and 3H-1,2-dithiole-3-thione ([@B123])   
  Stimulators of the GLT1 expression                                                                                                                             Penicillin, cephalosporin, ampicillin, estrogen, riluzole, and insulin ([@B34]; [@B10]; [@B50])                                    
  Activators of the GLT1 translation                                                                                                                             Pyridazine and LDN/OSU-0212320 ([@B22]; [@B129])                                                                                   
  GABA receptor antagonists                                                                                                                                      ([@B133])                                                                                                                          
  Epilepsy                                                                                                                                                       AED                                                                                                                                Valproic acid, lamotrigine, phenobarbital, gabapentin, felbamate, and topiramate ([@B33])
  Anticancer drug                                                                                                                                                Rapamycin ([@B45]; [@B57])                                                                                                         
  Allosteric potentiators of glutamine synthetase, regulators of AQP4 trafficking, interleukin 1 antagonists, and agonists or allosteric potentiators of TNFR2   ([@B124]) ([@B24])                                                                                                                 
  Ischemic stroke                                                                                                                                                Stimulators of the GLT1 expression                                                                                                 Ceftriaxone ([@B79]; [@B119]), carnosine ([@B98]), and tamoxifen ([@B63])
  Inhibitors of p53 activity                                                                                                                                     MicroRNA-29a ([@B80]; [@B81])                                                                                                      
  Stimulators of angiogenesis                                                                                                                                    Ecdysterone ([@B70]) and omega-3 polyunsaturated fatty acids ([@B122])                                                             

The astrocyte carries most of the extracellular glutamate. Therefore, damage to astrocytes affects their capability to perceive or respond to an increase in glutamate levels which leads to the destruction of the microenvironment near neurons causing an over-stimulation of NMDA receptors, responsible for changes in cognitive functions in the frontal cortex ([@B31]). Current studies have shown that the damage to astrocytes induced by Aβ is responsible for the reduced expression of GLT1 in AD. Therefore, drugs that target astrocytic glutamate transporters to ameliorate their expression and role represent a possible target for neurodegenerative syndromes. In this regard, there are two pharmacological approaches to increase GLT expression: either by increasing GLT1 promoter activation or by activating GLT1 translation ([@B92]; [@B61]). Among the compounds able to stimulate the expression of GLT1 already 48h after drug treatment, there are β-lactam antibiotics comprising penicillin and its derivatives, as well as cephalosporin antibiotics. Other mixtures such as ampicillin, estrogen, riluzole, and insulin have also been found to increase GLT1 expression ([@B34]; [@B10]; [@B50]) ([**Table 1**](#T1){ref-type="table"}). Instead, among compounds that have been found to activate the GLT1 translation ([**Table 1**](#T1){ref-type="table"}), we have a series of compounds based on pyridazine and LDN/OSU-0212320 ([@B22]; [@B129]). Finally, recent studies have correlated GABAergic neurotransmission with the pathological changes of AD ([@B65]). Damaged astrocytes produce a copious amount of GABA that is released to inhibit excitatory neurotransmission in the dentate gyrus. In addition to GABA, monoamine oxidase-B (MAO-B) has been reported to be altered on reactive astrocytes ([@B52]), and the enzyme is upregulated in the *post mortem* brain of individuals with AD ([@B96]). In an animal model of Alzheimer, it has been shown that the administration of GABA receptor antagonists ([**Table 1**](#T1){ref-type="table"}) improve long-term memory in the hippocampus ([@B133]).

HD is a disease that progressively destroys neurons in the brain and leads to severe motor and cognitive deficits. To date, no cure is available, but researchers have made progress that can lead to effective therapies. Numerous studies suggest that astrocytes may be intricated in HD. In particular, it has been observed that mHTT accumulations in striatal astrocytes are present in the brains of HD patients and in HD mouse models ([@B8]). Several HD mouse models have been used to evaluate the contribution of astrocytes to HD pathophysiology. In one of these studies, astrogliosis was evaluated as it frequently accompanies brain disorders. In conjunction with the start of symptoms, a high number of astrocytes showed mHTT inclusions and an important reduction in fundamental functional proteins. One of these proteins was Kir4.1 ([@B115]). These results propose that mHTT is correlated with early termination of the expression of essential functional astrocyte proteins (e.g., Kir4.1), which modifies the function of astrocytes without triggering astrogliosis. Furthermore, striatal astrocytes of HD mice show depolarized membrane potentials and lower membrane conductances when mice are symptomatic. This is owing to the function and lower expression of the Kir4.1 channels. Deficiencies in latent membrane potential were recovered by selective release of Kir4.1 from adeno-associated viruses (AAV) and a specific astrocyte promoter. Furthermore, it has been observed that the loss of Kir4.1 currents in striatal astrocytes leads to reduced K^+^ spatial buffering, which leads to higher environmental K^+^ levels in HD mouse models. Therefore, the astrocytic channels Kir.4.1, and other astrocytic molecular mechanisms can represent appreciated targets for therapeutic development ([@B55]).

Other approaches currently being studied for HD therapy point to both to obtain information on the mechanisms of disease progression and to silence the expression of mHTT using antisense oligonucleotides. A new approach is to detect novel factors that increase neurogenesis and/or stimulate the reprogramming of endogenous neuroblasts and parenchymal astrocytes to produce new healthy neurons to substitute the lost ones and/or strengthen the neuroprotection of preexisting striatal and cortical neurons ([@B94]).

Regarding epilepsy, to date, more than 20 antiepileptic drugs (AEDs) ([**Table1**](#T1){ref-type="table"}) have been developed, including valproic acid, lamotrigine, phenobarbital, gabapentin, felbamate, and topiramate ([@B33]). Despite this, ∼30% of patients respond poorly to treatment ([@B62]). In contrast, 70% of patients can attain long-term remission under AED treatment. However, many AEDs are associated with adverse side effects that are experienced by a substantial number of patients. Thus, significant unmet medical needs still must be overcome for the real and safe treatment of epilepsy. Many studies have suggested that inequities between excitatory and inhibitory signals may cause epilepsy ([@B125]; [@B6]). AEDs currently used to stop epileptic seizures act mostly by blocking ion channels and inhibiting neuronal excitability. Rapamycin, which was approved by the FDA as an anticancer drug ([**Table 1**](#T1){ref-type="table"}), has been demonstrated as another potential antiepileptic agent with broader clinical relevance ([@B45]; [@B57]). Unfortunately, rapamycin can inhibit cell proliferation and motility; thus, the safety of long-term rapamycin treatments must be assessed in advance. However, the role of the mTOR inhibition strategy for the treatment of epilepsy remains viable ([@B93]). Today, it is clear that astrocytes play prominent roles in information processing in the epileptic brain. Insights gleaned from careful studies of the properties of reactive astrocytes suggest several novel targets for drug development ([**Table 1**](#T1){ref-type="table"}), including allosteric potentiators of glutamine synthetase, regulators of AQP4 trafficking, interleukin 1 antagonists, and agonists or allosteric potentiators of TNFR2 ([@B124]) ([@B24]).

To date, pharmacological treatments for ischemia/reperfusion have palliative effects and require almost immediate administration after damage ([@B117]). To overcome this problem, it is indispensable to find new treatments focused mainly on long-term neuroprotection. Strategies targeting astrocytes may be an option as the increase in astrocyte survival during ischemic stress is connected with increased neuronal survival. It has been observed that induction of glial-specific purinergic receptor activation (P2Y1R) leads to greater consumption of mitochondrial O~2~ and stimulation of ATP production by astrocytes thus reducing neuronal damage to astrocytes and cell death and therefore brain damage ([@B139]; [@B69]). Furthermore, infarct area improved even after administration of TGF-α ([@B97]). This treatment also led to a significant functional recovery in rats after MCAO ([@B53]). Other experiments indicate that another therapeutic potential involves the increase in astrocytic glutamate transport after stroke. Thus, the increased expression of the glutamate transporter GLT-1 in astrocytes with ceftriaxone ([**Table 1**](#T1){ref-type="table"}) ([@B79]; [@B119]) protects neurons from ischemia ([@B18]). Other compounds that improve neurological function and reduce the infarct area are carnosine ([@B98]) and tamoxifen ([@B63]) ([**Table 1**](#T1){ref-type="table"}). Both substances preserve the expression of GLT-1 on astrocytes by reducing glutamate levels and attenuating the consequent excitotoxicity. Another target for stroke therapy is p53 ([**Table 1**](#T1){ref-type="table"}) since inhibition of p53 activity has been shown to hinder astrocyte activation and glutamate intake ([@B2]). Even microRNAs, approximately of which are expressed in astrocytes as microRNA-29a, appear to be intricate in the control of cerebral ischemia and may represent targets for improving stroke outcome ([@B80]; [@B81]). More recently, reference is made to cell therapy which aims at finding cells that can induce regeneration. Astrocyte transplantation conducts to recovery of axonal myelination, variation of the immune response, and issue of neurotrophic factors that prevent oxidative stress and excitotoxic injury ([@B17]). Other studies have suggested to astrocytes a therapeutic target based on their control by genetic change of proteins associated to the immune response and exacerbation of reactivity and cytotoxicity ([@B75]). Finally, it was observed that post-stroke angiogenesis not only ameliorate blood perfusion in the ischemic area but also supports cerebral parenchymal cells, comprising astrocytes, the issue of neurotrophic factors, to stimulate neurogenesis, which therefore improves remodeling cerebral and long-term neurological function after stroke ([@B136]). Consequently, angiogenesis represents a valid reparative machinery that has been verified in numerous studies ([**Table 1**](#T1){ref-type="table"}). For example, treatment with ecdysterone ameliorates neurological function by improving astrocyte stimulation and angiogenesis after focal cerebral ischemia in rats ([@B70]). Transgenic overproduction of omega-3 polyunsaturated fatty acids in mice recovers post-stroke revascularization and increases endogenous angiogenesis by inducing angiopoietin 2 production in astrocytes, which consequently stimulated endothelial cell proliferation and BBB formation, proposing that the integration of omega-3 polyunsaturated fatty acids is a possible angiogenic treatment able to increase brain repair and improve long-term functional recovery after ischemic stroke ([@B122]).

Author Contributions {#s7}
====================

RS and RF made literature search and wrote the first draft of the manuscript. SC, RS and RF designed the aim of the review. All authors contributed to reading and approving the final version of the manuscript.

Conflict of Interest {#s8}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Lorenzo Di Cesare Mannelli, University of Florence, Italy

[^2]: Reviewed by: Livio Luongo, Second University of Naples, Italy; Caterina Scuderi, Sapienza University of Rome, Italy; Abbas Mirshafiey, Tehran University of Medical Sciences, Iran

[^3]: This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology

[^4]: †These authors have contributed equally to this work
